# A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

> **NCT03557411** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 42 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT03557411
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-09
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-07-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557411, "A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03557411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*